Here's my list of Australian cannabis predictions for 2023.
Make of them what you will, and in a year we'll re-visit and see how many (if any) of them are correct.
IHL-216A is a combination drug that combines CBD with any volatile anaesthetic agent, including isoflurane. IHL-216A has been designed to be administered soon after head trauma to reduce secondary brain injuries that lead to neurological deficits.
"This study highlights CBD, and its active metabolite, 7-OH-CBD, as potential preventative agents and therapeutic treatments for SARS-CoV-2 at early stages of infection."
From 1 May 2021, Australians living with Dravet syndrome, will have access to Epidiolex® (cannabidiol), a new treatment used in combination with at least two other anti-epileptic medicines on the PBS.